Bradley receives $2 million grant to study treatments for parvovirus

Document Type

News Article

Publication Date


Campus Unit

School of Medicine & Health Sciences


On March 10, David Bradley, PhD, an immunologist and executive director of the Center of Research Excellence for Avian Therapeutics for Infectious Diseases at the University of North Dakota School of Medicine and Health Sciences, received a peer-reviewed Research ND BIO grant of $2 million to assist in the research, development, and commercialization of a novel therapeutic for parvovirus infection in puppies and dogs.

The North Dakota Department of Commerce awarded Bradley $1 million through its Research ND BIO program that promotes the development and commercialization of products and processes through industry and university research partnerships. Research ND Bio provides matching funds to help companies pay for university research. Research ND Bio matched the $1 million awarded to Bradley from Avianax LLC, a joint venture between Intraglobal Biologics and the University of North Dakota.

According to the ASPCA, "Canine parvovirus is a highly contagious viral disease that can produce a life-threatening illness. The virus attacks rapidly dividing cells in a dog's body, most severely affecting the intestinal tract. Parvovirus also attacks the white blood cells, and when young animals are infected, the virus can damage the heart muscle and cause lifelong cardiac problems."